



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Lausanne, Switzerland

## \*CORRESPONDENCE

Blanca Molins  
✉ [bmolins@recerca.clinic.cat](mailto:bmolins@recerca.clinic.cat)

RECEIVED 13 June 2024

ACCEPTED 13 June 2024

PUBLISHED 21 June 2024

## CITATION

Molins B, Figueras-Roca M, Valero O, Llorens V, Romero-Vázquez S, Sibila O, Adan A, Garcia-Vidal C and Soriano A (2024) Corrigendum: C-reactive protein isoforms as prognostic markers of COVID-19 severity. *Front. Immunol.* 15:1447976. doi: 10.3389/fimmu.2024.1447976

## COPYRIGHT

© 2024 Molins, Figueras-Roca, Valero, Llorens, Romero-Vázquez, Sibila, Adan, Garcia-Vidal and Soriano. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: C-reactive protein isoforms as prognostic markers of COVID-19 severity

Blanca Molins<sup>1\*</sup>, Marc Figueras-Roca<sup>1,2</sup>, Oliver Valero<sup>3</sup>, Victor Llorens<sup>1,2</sup>, Sara Romero-Vázquez<sup>1</sup>, Oriol Sibila<sup>4</sup>, Alfredo Adan<sup>1,2</sup>, Carolina Garcia-Vidal<sup>5</sup> and Alex Soriano<sup>5,6</sup>

<sup>1</sup>Group of Ocular Inflammation: Clinical and Experimental Studies, Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Barcelona, Spain, <sup>2</sup>Institut Clínic d'Oftalmologia (ICOF), Hospital Clínic, Barcelona, Spain, <sup>3</sup>Statistical Department, Universitat Autònoma de Barcelona, Barcelona, Spain, <sup>4</sup>Respiratory Department, Hospital Clínic of Barcelona-IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, <sup>5</sup>Department of Infectious Diseases, Hospital Clínic of Barcelona-IDIBAPS, University of Barcelona, Barcelona, Spain, <sup>6</sup>CIBERINF, Barcelona, Spain

## KEYWORDS

C-reactive protein, COVID-19, isoforms, inflammation, prognosis

## A corrigendum on

### C-reactive protein isoforms as prognostic markers of COVID-19 severity

by Molins B, Figueras-Roca M, Valero O, Llorens V, Romero-Vázquez S, Sibila O, Adán A, García-Vidal C and Soriano A (2023). *Front. Immunol.* 13:1105343. doi: 10.3389/fimmu.2022.1105343

In the published article, there was an error in the Funding statement. The first sentence was incorrectly written as “This work was funded by the Ministry of Science and Innovation of Spain, “Instituto de Salud Carlos III”, “Fondo de Investigación Sanitaria” (grant number PI19/00265), and Funds FEDER “Una manera de hacer Europa”. It should appear as “This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/00265 and co-funded by the European Union”. The correct Funding statement appears below.

## Funding

This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project PI19/00265 and co-funded by the European Union. We are indebted to the Fundació Glòria Soler for its contribution and support to the COVIDBANK of HCB-IDIBAPS. This work was financed by *ad hoc* patronage funds for research on COVID-19 from donations from citizens and organizations to the Hospital Clínic de Barcelona-Fundació Clínic per a la Recerca Biomèdica.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.